Senzime secures the first sales in the US market
News: Uppsala, March 30, 2020. Senzime AB (publ) today announces that the company has received its first orders in the US which marks the sales start in the fully owned subsidiary Senzime Inc. In October 2019 Senzime announced that the company's medical device system for monitoring neuromuscular blockade, TetraGraph, had received 510 (k) approval by the US Food and Drug Administration, FDA. Senzime immediately began the establishment of a fully owned subsidiary - Senzime Inc. - which was registered in Florida in early December 2019 at the same time as the recruitment of a head of US